The funding round was led by Bain Capital Life Sciences and brought in a new investor in Janus Henderson Investors
HeartFlow secures $215m in a Series F round. (Credit: Robina Weermeijer on Unsplash)
HeartFlow, an American medical technology company, has raised $215m in a Series F funding round for its artificial intelligence (AI)-enabled portfolio of precision heart care products.
The funding round was led by Bain Capital Life Sciences. It saw the participation of new investor Janus Henderson Investors alongside existing investors such as Hayfin Capital Management, Baillie Gifford, HealthCor, Capricorn Investment Group, USVP, Martis Capital, and Wellington Management.
Bain Capital Life Sciences managing director Nicholas Downing said: “HeartFlow is a leader in precision heart care and its AI-enabled products promise to help physicians more effectively diagnose and treat heart disease, which continues to be the leading cause of death in the U.S.
“We look forward to supporting the company’s commitment to improving cardiovascular care for patients as it heads into this exciting next chapter of growth.”
HeartFlow said that the new funding will help the company cope with the demand for its commercial products. It will also enable the company to advance its product portfolio to help physicians in diagnosing coronary artery disease (CAD) and support in taking treatment decisions.
The California-based company offers non-invasive coronary artery anatomy through RoadMap analysis, physiology with HeartFlow FFRCT, and plaque information with Plaque analysis, based on coronary computed tomography angiography (CCTA). The products are said to make physicians better understand a patient’s coronary artery disease.
In October 2022, the AI-powered Plaque analysis and RoadMap analysis were both granted 510 (k) clearance from the US Food and Drug Administration (FDA).
HeartFlow CEO John Farquhar said: “HeartFlow has built a strong intellectual property portfolio, brought to market the only combined anatomy, physiology and plaque analysis to help diagnose and treat heart disease, and is now in over 725 hospital systems worldwide with over 180,000 patients served to date.
“The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team and the opportunity in front of us. We appreciate the support of our investors, both existing and new, who share HeartFlow’s vision to build a new standard of care for people at risk of heart disease.”